This trial is evaluating whether ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% will improve 1 primary outcome and 7 secondary outcomes in patients with Eczema. Measurement will happen over the course of 52 weeks.
This trial requires 1500 total participants across 2 different treatment groups
This trial involves 2 different treatments. ARQ-151 Cream 0.15% Or ARQ-151 Cream 0.05% is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
There are many causes of eczema, including infections during the first months of a child’s life. Poorly insulated skin during this period can be a contributing factor. Other factors may include the mother’s allergies and allergies to various foods, and the fact that eczema often occurs at an early age. A strong correlation was found between eczema and infection with "H. pylori", or "C. pylori". The strongest correlations were found with wheezing or asthma, or both in children, especially if they are overweight. Some of the factors listed above may be responsible. The immune system may be less functional in eczema infants, due to their inexperience in battling infection.
Eczema is a skin condition that affects at least 1% to 2% of the US population and that can persist for years with no known cause. In most cases, eczema appears in childhood, although adolescence or early adulthood may be when the condition becomes lifelong. This skin disease is characterized by dry, itchy, rashy, itchy or greasy skin; often with a fringe of hair. It may result in problems such as a compromised immune system, allergies, eczema-related sinus infections and skin cancer. Ecdysplasia is a skin disorder characterized by thickening of the skin.
Nearly four out of five children and one out of four adults in the United States have one or more eczema symptoms in the last month. This condition, which can affect people at all ages, has risen in prevalence, especially in schools at all age groups. Many people, though, are hesitant to talk to their physicians about it due to fear, lack of knowledge about the condition, and shame about their appearance.
The presentation of symptoms of eczema reflects the active state of the disease in the previous 24 hrs. Patients presenting with more severe eczema are more likely to have a more acute clinical course, presenting a greater number of symptoms compared with the non-active state. This is the first study to show a correlation between disease activity and symptoms in patients with eczema with a standard disease activity index.
This is the first time that this issue has been addressed. Families with atopic dermatitis can be a clue that there may be genetic factors associated with the occurrence and persistence of eczema; though, not all families with eczema have relatives with atopic dermatitis. Findings from a recent study provides preliminary evidence for a genetic component in children with eczema.
Arq-151 cream 0.15% and 0.05% are typically used in combination with any other treatments as of 2011-2012. For mild eczema or atypical eczema, either formulation provides acceptable relief by reducing moderate and severe discomfort.
These data confirm a significant improvement in lesion severity and itch relief following administration of arq-151 cream 0.15% with no treatment compared to a placebo treatment in patients with persistent AD, and also in the presence of clinically significant eczema.
The average age a child gets eczema is 5.6 years old at onset of symptoms, whereas the average age at onset of symptoms in adults is 43.6 years. It is more common in infants, toddlers, teenagers and young adults. Men and women are equally affected. Ethnicity (p>0.006,) has an important influence on eczema disease prevalence. It is more common in non-White children.
Findings from a recent study demonstrated that 0.15% and 0.05% products of arq-151 creams demonstrated good efficacy in the treatment of eczema. Thus, the use of both preparations as monotherapy and with tretinoin or retinoid therapy is recommended. Findings from a recent study justify additional studies investigating optimal dosing of arq-151 cream.
ARQ-151 is safe and effective and can be used in patients with moderate to severe atopic dermatitis and in those who are unsuitable for a prescription topical corticosteroid.